Literature DB >> 30970522

Growth arrest specific transcript 5 in tumorigenesis process: An update on the expression pattern and genomic variants.

Soudeh Ghaforui-Fard1, Mohammad Taheri2.   

Abstract

Growth arrest-specific 5 (GAS5) is a long non-coding RNA (lncRNA) with diverse functions in regulation of gene expression. Most studies have reported a role for this lncRNA in induction of cell apoptosis and suppression of tumorigenesis process. Although few studies demonstrated up-regulation of this lncRNA in tumor tissues compared to non-tumor tissues of the same origin, the results of in vitro functional studies mostly support the tumor suppressor role for GAS5. A number of recent studies have also shown associations between genomic variants of this gene and risk of cancer in some populations. The role of this lncRNA in modulation of response to anti-cancer regimens has been verified through both in vitro and clinical studies. Taken together, this lncRNA is a putative biomarker and therapeutic target in human malignancies.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Cancer; GAS5; lncRNA

Mesh:

Substances:

Year:  2019        PMID: 30970522     DOI: 10.1016/j.biopha.2019.108723

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  9 in total

1.  Association of Long Non-Coding RNA Growth Arrest-Specific 5 Genetic Variants with Diabetic Retinopathy.

Authors:  Chee-Ming Lee; Yi-Sun Yang; Edy Kornelius; Chien-Ning Huang; Min-Yen Hsu; Chia-Yi Lee; Shu-Yen Peng; Shun-Fa Yang
Journal:  Genes (Basel)       Date:  2022-03-25       Impact factor: 4.141

2.  Long non-coding RNA GAS5 overexpression inhibits M2-like polarization of tumour-associated macrophages in SMCC-7721 cells by promoting PTEN expression.

Authors:  Xun Wang; Fang-Yuan Li; Wei Zhao; Zhi-Kang Gao; Bin Shen; Hao Xu; Yan-Feng Cui
Journal:  Int J Exp Pathol       Date:  2020-11-04       Impact factor: 1.925

3.  lncRNA GAS5‑mediated miR‑23a‑3p promotes inflammation and cell apoptosis by targeting TLR4 in a cell model of sepsis.

Authors:  Zhenping Gao; Dan Huang
Journal:  Mol Med Rep       Date:  2021-05-13       Impact factor: 2.952

4.  Genetic Variants of lncRNA GAS5 Are Associated with the Clinicopathologic Development of Oral Cancer.

Authors:  Ming-Hong Hsieh; Hsueh-Ju Lu; Chiao-Wen Lin; Chia-Yi Lee; Shang-Jung Yang; Pei-Hsuan Wu; Mu-Kuan Chen; Shun-Fa Yang
Journal:  J Pers Med       Date:  2021-04-26

Review 5.  The Non-Coding RNA GAS5 and Its Role in Tumor Therapy-Induced Resistance.

Authors:  George I Lambrou; Kyriaki Hatziagapiou; Apostolos Zaravinos
Journal:  Int J Mol Sci       Date:  2020-10-15       Impact factor: 5.923

6.  GAS5 rs2067079 and miR-137 rs1625579 functional SNPs and risk of chronic hepatitis B virus infection among Egyptian patients.

Authors:  Rania H Mahmoud; Enas Mamdouh Hefzy; Olfat G Shaker; Tarek I Ahmed; Noha K Abdelghaffar; Essam A Hassan; Amal A Ibrahim; Doaa Y Ali; Mohamed M Mohamed; Omayma O Abdelaleem
Journal:  Sci Rep       Date:  2021-10-08       Impact factor: 4.379

7.  LncRNA GAS5 rs145204276 Polymorphism Reduces Renal Cell Carcinoma Susceptibility in Southern Chinese Population.

Authors:  Xiaoyao Xiang; Linfa Chen; Jiawen He; Guoda Ma; You Li
Journal:  J Inflamm Res       Date:  2022-02-18

Review 8.  Long Noncoding RNA GAS5 in Breast Cancer: Epigenetic Mechanisms and Biological Functions.

Authors:  Elena A Filippova; Marina V Fridman; Alexey M Burdennyy; Vitaly I Loginov; Irina V Pronina; Svetlana S Lukina; Alexey A Dmitriev; Eleonora A Braga
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 5.923

9.  Psorachromene Suppresses Oral Squamous Cell Carcinoma Progression by Inhibiting Long Non-coding RNA GAS5 Mediated Epithelial-Mesenchymal Transition.

Authors:  Tong-Hong Wang; Yann-Lii Leu; Chin-Chuan Chen; Tzong-Ming Shieh; Jang-Hau Lian; Chi-Yuan Chen
Journal:  Front Oncol       Date:  2019-11-05       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.